Seeking Alpha

Merck gets FDA nod for delayed-release Noxafil

  • The FDA approves Merck's (MRK -0.1%) 100 mg delayed-release Noxafil tablets.
  • The product is indicated for "the prophylaxis of invasive Aspergillus and Candida infections." (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs